Compare Equinix Inc (EQIX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Natera Inc. Common Stock — how do they compare? Equinix Inc trades at $1,000 (market cap $98.27B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Equinix Inc is the larger of the two by market cap, and Equinix Inc pays a 2.07% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Natera Inc. Common Stock for 0 Days on average.
| EQIX | NTRA | |
|---|---|---|
Market Cap | $98.27B | $57.03B |
Volume | 450,557 | 1,131,157 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $425.64 |
52-Week Low | $726.09 | $179.42 |
Typical Hold Time | 110 Days | 0 Days |
Enterprise Value | $119.40B | $56.18B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,019.40, down 1.28% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue growth to $9.22B in 2025 with a net income margin of 15.63%, though recent quarters show mixed earnings performance with two misses and one beat. Analyst consensus remains strongly bullish with 75% buy ratings and a $1,250 price target, while the company continues expanding its AI-driven data center capacity with $5B-$7B annual investments.
EQIX presents growth potential through AI infrastructure demand and interconnection services, supported by strong institutional backing. However, elevated valuation ratios (P/E 64.09, P/S 10.02) and substantial capital expenditures creating negative cash flow pose risks. The stock's outlook depends on successful execution of expansion plans and maintaining premium pricing power in the competitive data center REIT sector.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
